Ambani Orgochem Ltd (AMBANIORGO) is currently trading at 174.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ambani Orgochem Limited manufactures specialty chemicals for paints, coatings, adhesives, textiles, paper, carpets, construction, fragrances, personal care and related industrial applications. Its portfolio spans peroxide derivatives, salicylic acid and salicylates, metal octoates, and water-based acrylic coatings and adhesives, supported by four manufacturing facilities across Tarapur and Dahej. The company reported a sharp H1 FY27 improvement, with consolidated revenue rising 54.87% year on year to Rs. 171.22 crore and net profit increasing to Rs. 3.45 crore from Rs. 19.07 lakh. EBITDA grew 43% to Rs. 11.32 crore, although profitability remains relatively modest compared with revenue. Ambani Orgochem Limited operates in highly specialized organic peroxides, where management estimates only five or six global manufacturers and three Indian producers, including the company. This niche positioning, together with long-standing customer relationships and technical acceptance by multinational customers, may provide stronger defensibility than its broader coatings business. The company is expanding acrylic capacity because Tarapur is reportedly fully utilized and existing customers face supply constraints. Management expects the expansion to be EBITDA accretive from inception because it extends existing manufacturing infrastructure without a substantial increase in fixed costs. Growth remains exposed to execution and logistics risks. Dahej peroxide utilization is approximately 40%, partly because geopolitical disruptions have constrained transportation of Class 5.2 products toward GCC markets, while the proposed warrant funding and future expansion require shareholder, regulatory and capital-allocation discipline.

Over the past 52 weeks, Ambani Orgochem Ltd has traded between a low of ₹94.90 and a high of ₹184.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ambani Orgochem Ltd has a market capitalization of approximately 147.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ambani Orgochem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.16 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 147.63 Cr, Ambani Orgochem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ambani Orgochem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ambani Orgochem Ltd is 32.16. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Ambani Orgochem reported total income of ₹171.22 crore for H1 FY27, up 54.87% from ₹110.56 crore in H1 FY26. Net sales turnover was ₹169.98 crore.

The EGM agenda covered reclassification of authorised share capital, amendments to the MOA and AOA, adoption of Table F under the Companies Act, and a proposed preferential issue of convertible warrants.

The company informed the exchange that its board meeting is scheduled for 15-Oct-2026 to consider and approve unaudited results for the half-year ended September 2026.